Zanolimumab, a human monoclonal antibody targeting CD4 in the treatment of mycosis fungoides and Sézary syndrome.
BACKGROUND
The most common type of primary cutaneous T cell-lymphomas (CTCLs), which are characterised by a clonal proliferation of malignant skin-homing CD4(+) lymphocytes, is mycosis fungoides (MF) and its rare leukaemic variant Sézary syndrome (SS).


OBJECTIVE
Zanolimumab is a high affinity human monoclonal IgG1k antibody, targeting the CD4-molecule. It exhibits cytotoxic and antiproliferative effects and has previously shown efficacy in CTCLs.


METHODS
Literature and reference research was done by using Pubmed and updates of ongoing studies were taken from American Society of Clinical Oncology (ASCO) and American Society of Hematology (ASH )annual meeting abstracts.


RESULTS
This article gives an overview about efficacy, tolerability and safety as well as chemistry, pharmacodynamics and pharmacokinetics of zanolimumab in the treatment of CTCLs.
Mestel
Dominik Sebastian
DS
Charité Universitaetsmedizin Berlin, Skin Cancer Center Charite, Department of Dermatology and Allergy, Charitéplatz 1, DE-10117, Berlin, Germany.
Beyer
Marc
M
Möbs
Markus
M
Steinhoff
Matthias
M
Sterry
Wolfram
W
Assaf
Chalid
C
D000911:Antibodies, Monoclonal / Q000276:immunology / Q000494:pharmacology / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D015704:CD4 Antigens / Q000276:immunology*; D002986:Clinical Trials as Topic; D006801:Humans; D009182:Mycosis Fungoides / Q000628:therapy*; D011788:Quality of Life; D012751:Sezary Syndrome / Q000628:therapy*
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D015704:CD4 Antigens; C520522:zanolimumab